Median Technologies, Microsoft ink Big Data deal for cancer diagnostics

Median Technologies (EPA:ALMDT) and Microsoft (NSDQ:MSFT) said today they inked a deal to develop new cancer detection, diagnosis and monitoring methods using “big data” analytics.

Through the deal, Median Technologies will use its Ibiopsy imaging biomarker phenotyping system with Microsoft’s Azure cloud computing platform to provide capabilities for processing and analyzing medical images and extracting biomarkers for cancer diagnosis and treatment.

“Precision Medicine is about to revolutionize how diagnostic and biological data is used to pinpoint and deliver care that is preventive, targeted and effective. Extracting biomarkers of disease from medical images is at the core of the Precision Medicine effort. Big Data computing and analytics will allow efficient processing and analysis of imaging biomarkers which is essential for early detection of cancer and monitoring of new targeted cancer treatments. Our collaboration with Microsoft will allow us to deliver these solutions into routine clinical practice on a global scale on the Azure Cloud Computing platform,” Median CEO Fredrik Brag said in a press release.

Median said that its Ibiopsy will eventually be made available to medical facilities and physicians in the U.S., Europe and Asia to enable more advanced image processing and data analytics for next-gen personalized cancer therapies.

“Microsoft Innovation teams are committed to providing their technical expertise to health professionals who use medical images in their daily routine. We are proud to collaborate with Median on the Ibiopsy project and to bring innovative technologies at the service of cancer research. Indeed, we are, more than ever committed to addressing the biggest challenges in cancer detection, diagnosis and monitoring, by offering access to the latest and most innovative technologies. By taking advantage of the powerful Microsoft Azure cloud platform, Ibiopsy will provide faster imaging and health data analysis and will accelerate the discovery and delivery of new biomarkers for cancer diagnosis and treatment monitoring,” Mircosoft France CTO Bernard Ourghanlian said in a press release.

The companies said they will work together to help medical centers utilize its Azure system, and that they will focus on the development of novel predictive analytic methods based on machine learning and encryption capabilities available on Azure.

The post Median Technologies, Microsoft ink Big Data deal for cancer diagnostics appeared first on MassDevice.

from MassDevice http://ift.tt/28QeUEw